Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem
Top Cited Papers
- 8 April 2015
- journal article
- Published by Springer Nature in Drugs & Aging
- Vol. 32 (4) , 261-269
- https://doi.org/10.1007/s40266-015-0258-9
Abstract
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA virus and member of the Paramyxoviridae family of the genus Pneumovirus that was first reported as a major pathogen in pediatric populations. However, since its discovery, RSV has not infrequently been detected in adults. Reinfection occurs throughout life, with more severe disease occurring in older adults, immunocompromised patients, and those with underlying cardiopulmonary disease. Initially described as the cause of nursing home outbreaks of respiratory disease, there is a now significant body of literature describing the clinical importance of RSV in older adults in a multitude of settings including long-term care, adult daycares, and in community-dwelling adults. Moreover, recent reports from China and other countries emphasize that RSV is a global pathogen that will become increasingly important in developed nations with aging populations. Annual attack rates in the USA range from 2 to 10 % in community-dwelling older adults and 5–10 % in older adults living in congregate settings. Population-based calculations of the proportion of acute respiratory illnesses attributable to RSV estimate that 11,000 elderly persons die annually in the USA of illnesses related to RSV infection. Clinical manifestations of RSV infections are similar to that of other viral respiratory pathogens and include cough, nasal congestion, rhinorrhea, sore throat, and dyspnea. Lower respiratory tract disease is common and may result in respiratory failure (8–13 %) or death (2–5 %). Recent advances in molecular diagnostics have made it possible to rapidly identify RSV infection using nucleic acid amplification tests, although clinicians will need to suspect the diagnosis when viral activity is high. At the present time, treatment is supportive. Effective antiviral agents for the treatment and vaccines for prevention of RSV remain a significant unmet medical need in the older adult population.Keywords
This publication has 111 references indexed in Scilit:
- Influenza and RSV make a modest contribution to invasive pneumococcal disease incidence in the UKPublished by Elsevier ,2013
- The Incidence and Clinical Burden of Respiratory Syncytial Virus Disease Identified through Hospital Outpatient Presentations in Kenyan ChildrenPLOS ONE, 2012
- Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and CoronavirusClinical Infectious Diseases, 2012
- Simple Method for Combining Sputum and Nasal Samples for Virus Detection by Reverse Transcriptase PCRJournal of Clinical Microbiology, 2012
- Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008Clinical Infectious Diseases, 2012
- The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related IllnessChest, 2011
- The Potential Influence of Common Viral Infections Diagnosed during Hospitalization among Critically Ill Patients in the United StatesPLOS ONE, 2011
- Risk Factors for Respiratory Failure Associated with Respiratory Syncytial Virus Infection in AdultsThe Journal of Infectious Diseases, 2009
- Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantationHaematologica, 2009
- Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military trainingInfluenza and Other Respiratory Viruses, 2007